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Survival for dialysis patients is dismal. They have an adjusted mortality rate 6.5-7.9 times 
higher than the general population. Kidney transplant (KT) recipients enjoy significant 
survival and quality of life advantages compared to remaining dialysis-dependent (1-5). 
Unfortunately, kidney demand far exceeds supply, with over 90,000 on the wait list (5). 
Highly sensitized patients constitute an increasingly large part of the wait list (6).  
 
Advancements in desensitization have allowed for KT across previously insurmountable 
immunological barriers; however, incompatible live donor kidney transplantation 
(ILDKT) is in its nascency and the literature is limited by single-center data, small 
sample sizes, and publication bias. ILDKT risks are generally considered to be higher 
than for compatible KT, but these risks have never been quantified precisely. Chapter 2 
does precisely this using primary data collected from 22 U.S. transplant centers, 
constituting the largest cohort of ILDKT patients in existence.  
 
ILDKT risks are not limited to recipients. The federal government provides strict 
oversight of transplant outcomes. Chapter 2 quantifies the regulatory risk centers assume 
when they transplant immunologically high-risk patients.  
 
IKT patients are also at elevated risk of antibody-mediated rejection (AMR), which 
mediates much of the graft loss in ILDKT. Chapter 3 details the formation of the world's 
largest cohort of AMR patients, defined using strict clinical, pathological, and 
 iii 
immunologic criteria, and quantification of the risk of graft loss associated with AMR by 
transplant type. 
 
There exists an uncommon, but virulent phenotype of AMR in ILDKT patients that is 
rapid in onset, severe in the graft dysfunction it causes, difficult to treat, and immediately 
graft-threatening without prompt action. Chapter 4 describes these patients in detail and 
compares the early rescue rate and impact of the severe AMR episode on the 
development of transplant glomerulopathy between salvage modalities, offering novel 
insight into the management of this challenging and devastating ILDKT complication.  
 
Overall, this dissertation explores the risk of ILDKT to patients and centers, and delves 
into particular aspects of AMR within the context of ILDKT. 
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CHAPTER 1 - Introduction: A Broad Overview of Kidney 
Transplantation in the Immunologically High-Risk Patient 
 
For patients with end stage renal disease, their survival on dialysis is dismal. Dialysis-
dependent patients have an adjusted all-cause mortality rate 6.5-7.9 times higher than the 
general population (5). Kidney transplant (KT) recipients enjoy significant survival and 
quality of life advantages compared to remaining dialysis-dependent (1-4), including a 
reduction in all-cause mortality to 1.0-1.5 times higher than the general population. 
Unfortunately, the demand for kidneys far exceeds the supply, with over 90,000 on a wait 
list that grows 4-8% annually (5, 7).  
 
In 1969, cross match testing was introduced, allowing HLA-compatible KT, and thus 
significantly diminishing the common complication of hyperacute rejection and its 
concomitant graft loss (8).  This allowed transplantation to proceed more safely and with 
more reliable outcomes. The introduction of more sensitive methods of antibody 
detection, including flow cytometric crossmatching and the Luminex platform has made 
compatible KT even safer; however, patients with broad pre-existing sensitivities (from 
exposure to foreign antigens through previous transplants, pregnancies, or blood 
transfusions) or hard-to-match blood types have found it much more difficult, and in 
some cases, impossible, to find a compatible graft, relegating them to a de facto 
permanent position on the wait list. This disparity has widened significantly over time. 
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Currently, nearly 40% of candidates on the wait list are sensitized (9, 10), prompting 
many centers, especially those with prolonged wait lists, to aggressively utilize available 
organs, even suboptimal ones (11). In an effort to ameliorate the supply-demand 
mismatch, kidney paired donation, the so-called “domino transplants,” were developed to 
offer hope to incompatible patients (12, 13), though the current volume of paired 
donations is not enough to help the vast majority of incompatible transplant candidates 
(14).  
 
Advances in desensitization protocols have allowed for transplantation across antibody 
barriers that used to be contraindications to transplant (15-18). Incompatible live donor 
kidney transplantation (ILDKT) is becoming an increasingly utilized approach to treating 
highly sensitized patients, particularly because of compelling evidence that patients 
undergoing desensitization and subsequent ILDKT have a two-fold survival benefit 
compared to remaining on dialysis waiting for a compatible KT (15). Some centers now 
incorporate kidney-paired donation and desensitization protocols to improve further 
matching between donors and recipients (18-22). 
 
Desensitization works by eliminating circulating antibody and/or minimizing antibody 
production. The physical removal of antibody from the circulation can be accomplished 
through plasmapheresis (PP), plasma exchange, or immunoadsorption (23). Intravenous 
immunoglobulin (IVIg) functions to abrogate the effects of antibody through a variety of 
mechanisms, but its most immediate effect is to neutralize circulating antibody (24, 25). 
The use of complement inhibitors halts the complement-mediated destruction of foreign 
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cells that have been targeted for destruction by antibody binding (26, 27). The inhibition 
of antibody production can be achieved through splenectomy, which removes antibody-
producing plasma cells and their precursor cells (28). Several pharmacologic agents are 
also available to prevent antibody production. Rituximab, an anti-CD20 monoclonal 
antibody, destroys pre-B and mature B lymphocytes before they can become antibody-
producing plasma cells (29). Proteasome inhibition is achieved by bortezomib, which 
induces apoptosis of plasma cells (30, 31).   
 
A number of combinations of these therapies have been used, but the three most widely 
published protocols are those of the Johns Hopkins Hospital, the Mayo Clinic, and 
Cedars-Sinai Medical Center. The Hopkins protocol involves every-other-day pre-
transplant PP followed by post-PP low-dose IVIg (32). At the initiation of PP and IVIg, 
patients are also started on tacrolimus and mycophenolate mofetil. At the time of 
transplant, patients are prescribed induction therapy and steroids. Patients also receive 
post-transplant PP and IVIg. Alternatively, the Mayo Clinic protocol involves pre-
transplant plasma exchange, induction with anti-thymocyte globulin, and maintenance 
immunosuppression with tacrolimus, prednisone, and mycophenolate mofetil (27). 
Patients are given 1200 mg of the C5-complement inhibitor eculizumab immediately 
prior to transplantation, 600 mg on post-operative day 1, and then 600 mg weekly for 
four weeks. The original Cedars-Sinai protocol involved the administration of monthly 




While desensitization and ILDKT allow patients to come off the transplant list and enjoy 
the survival and quality of life benefits of kidney transplantation (3, 15), it has created a 
cohort of patients at an unusually high risk of antibody-mediated rejection (AMR), a 
major threat to long-term graft survival. While unsensitized, compatible recipients can 
develop de novo AMR at a rate of 3-7 percent (35, 36), patients with donor-specific 
antibody (DSA) prior to transplantation have a 35% risk of developing AMR (35). Blood 
group incompatible patients have a nearly 10% risk of AMR (37).  
 
AMR, which is the result of the body’s humoral arm of the immune system, leads to a 
number of characteristic histologic changes within the allograft and is primarily directed 
against the endothelium of the microvasculature (38). Hallmarks of AMR are deposition 
of complement components C3d/C4d (though recent updates to the Banff Classification 
of Rejection now allow for C4d-negative AMR (39)), peritubular capillaritis, glomerulitis, 
thrombotic microangiopathy, interstitial fibrosis and/or hemorrhage, tubular atrophy, and 
microvascular thrombosis (40). Clinically, these patients often present with decreased 
urine output, hypertension, pyuria, proteinuria, and an acute rise in serum creatinine--a 
late finding indicating considerable allograft damage. Occasionally, patients will present 
with fever and tenderness, pain, or swelling over the graft. The treatment of AMR 
typically involves the same therapies as desensitization (26, 28, 31, 41-43). Importantly, 
the development of AMR, even subclinical AMR, is associated with significantly reduced 
graft survival (44-46). 
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And while ILDKT has opened the possibility for highly sensitized patients to benefit 
from KT, a number of significant challenges have thus far limited more widespread 
adoption of KT. The first limitation relates to the current state of the body of the ILDKT 
literature. Thus far, all of the studies on ILDKT are single-center studies, most often 
dominated by a few relatively high-volume centers (15, 27, 34, 47), and therefore subject 
to the limitations of relatively small sample sizes, publication bias, and significant 
heterogeneity of patient populations, desensitization and post-transplant management. 
Other factors limiting more widespread adoption of ILDKT is that it is labor- and 
resource-intensive, even by transplant center standards. Furthermore, tolerance for risk in 
the utilization of suboptimal organs varies dramatically across centers (11), and so it 
stands to reason that many transplant surgeons are reluctant to take on additional risk in 
the form of ILDKT. This aversion to risk is compounded by the fact that solid organ 
transplantation is highly regulated by the Centers for Medicare & Medicaid Studies 
(CMS), with strict scrutiny of graft and patient outcomes using mandatory outcomes 
benchmarks (48). The risk adjustment models used by CMS do not currently account for 
ILDKT, meaning that ILDKT outcomes are held to the same standard as compatible KT 
(49). The current absence of consideration of this factor may create a disincentive for 
centers to perform ILDKT despite its documented benefits for highly sensitized patients. 
Indeed, a recent consensus conference on transplant center surveillance methods aptly 
noted, "Failure to adequately adjust outcomes for risk may cause programs to avoid 
performing transplants involving suitable but high-risk candidates and donors" (50).  
There is evidence to suggest that this is the case, which may limit access to 
transplantation for sensitized patients and lead to disposal of less-than-optimal but still 
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acceptable organs (51-53).  Furthermore, failure to account for high-risk candidates puts 
transplant centers in jeopardy of punitive regulatory action for what may be satisfactory 
outcomes when properly and accurately interpreted in light of candidates' true high-risk 
nature (54).   
 
The field of ILDKT has advanced tremendously in a relatively short amount of time, 
allowing for the transplantation of kidneys across previously impossible antibody 
barriers; however, a number of significant challenges to improving access to and 
outcomes of ILDKT remain. This dissertation seeks to address several of these challenges. 
ILDKT risks are generally considered to be higher than for compatible KT, but these 
risks have never been quantified precisely. Chapter 2 does precisely this by using primary 
data collected from 22 U.S. transplant centers, constituting the largest cohort of ILDKT 
patients in existence. Chapter 2 also quantifies the regulatory risk transplant centers 
assume when they transplant immunologically high-risk patients to address some of the 
regulatory disincentives to ILDKT that are currently in place. Chapter 3 details the 
formation of the world's largest cohort of AMR patients, defined using strict clinical, 
pathological, and immunologic criteria, and quantification of the risks of graft loss and 
death associated with AMR by transplant phenotype. Chapter 4 describes a subset of 
AMR patients who have a particularly aggressive form of AMR and compares the early 
rescue rate and impact of the severe AMR episode on the development of transplant 
glomerulopathy between salvage modalities, offering novel insight into the management 
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Incompatible live donor kidney transplantation (ILDKT) offers patients with donor-
specific anti-HLA antibody (DSA) a survival advantage over dialysis. Program Specific 
Reports (PSR) fail to account for ILDKT, placing this practice at regulatory risk. We 
collected DSA data, categorized as positive Luminex, negative flow (PLNF) (n=185), 
positive flow, negative cytotoxic (PFNC) (n=536), or positive cytotoxic crossmatch 
(PCC) (n=304), from 22 centers. We tested associations between DSA, graft loss, and 
mortality after adjusting for PSR model factors, using 9,669 compatible patients as a 
comparison. PLNF patients had similar graft loss; however, PFNC (aHR=1.64, 
95%CI:1.15-2.23, P=0.007) and PCC (aHR=5.01, 95%CI: 3.71-6.77, P<0.001) were 
associated with increased graft loss in the first year. PLNF patients had similar mortality; 
however, PFNC (aHR=2.04; 95%CI: 1.28-3.26; P=0.003) and PCC (aHR=4.59; 95%CI: 
2.98-7.07; P<0.001) were associated with increased mortality. We simulated CMS 
flagging to examine ILDKT's effect on flagging risk. Compared to equal-quality centers 
performing no ILDKT, centers performing 5%, 10%, or 20% PFNC had a 1.19, 1.33, and 
1.73-fold higher odds of flagging. Centers performing 5%, 10%, or 20% PCC had a 2.22, 
4.09, and 10.72-fold higher odds. Failure to account for ILDKT's increased risk places 
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Patients with anti-HLA donor-specific antibody (DSA) undergoing desensitization and 
subsequent live donor kidney transplantation (referred to as ILDKT, or incompatible live 
donor kidney transplantation, for the purposes of this manuscript) enjoy a two-fold 
survival benefit compared to similar patients who remain on dialysis while waiting for a 
compatible donor (15). For most highly sensitized patients the choice is not between 
ILDKT and a compatible (no DSA) transplant. Rather, long waits on dialysis and high 
mortality rates are the only alternatives to desensitization.  Currently, algorithms for 
calculating center-specific expected outcomes do not consider the survival benefit 
derived from ILDKT.  Furthermore, risk adjustments do not distinguish ILDKT from 
compatible transplants.  Based on a recent survey of U.S. transplant centers, ILDKT have 
become mainstream procedures, performed at approximately 50-70% of transplant 
centers nationwide (55).   
 
Single-center reports suggest that ILDKT outcomes are not as good as compatible kidney 
transplants (56-58).  However, differences in outcomes have not been well characterized 
outside of large volume, more experienced centers.  Regulatory organizations currently 
hold the outcomes of ILDKT patients to the same standard as compatible recipients, 
thereby potentially penalizing centers that perform these transplants.  Better outcome data 
from ILDKT will inform future decisions about changing risk adjustments to encourage 
transplant centers to help their patients more fully realize the survival benefits associated 
with desensitization and ILDKT.    
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In the development of the Program Specific Reports (PSR), centers are given "credit" for 
transplanting other high-risk groups.  For example, a 70-year old recipient faces a 30 
percent higher risk of graft loss at one year than a 30-year old recipient. However, the 
PSRs account for this, enabling a center to offer transplantation to the 70-year old 
without fear of adverse regulatory actions provided that its outcomes are on par with 
other centers transplanting 70-year olds (49). However, this is not the case for ILDKT: if 
risk does indeed exist with this practice, that risk is not currently captured in the PSRs, 
potentially increasing a center's risk of flagging and investigation by the Centers for 
Medicare & Medicaid Studies (CMS).  
 
We hypothesized that ILDKT is associated with an increased risk of graft loss and death 
compared to compatible live donor kidney transplantation. To quantify this risk in the 
context of the PSRs, we created a multicenter collaboration linking anti-HLA DSA 
strength of ILDKT recipients to other data already reported to the Scientific Registry of 
Transplant Recipients (SRTR). Then, to examine the effect of ILDKT on the risk of CMS 
flagging, we conducted stochastic simulations of CMS center evaluations based on the 




Study Population and Incompatible Live Donor Kidney Transplantation Definition 
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We studied adult (>18 years of age), live donor, kidney-only recipients from 22 U.S. 
transplant centers through December 2011. The population included all ILDKT 
performed at a given center as well as all compatible live donor kidney transplants 
performed at that center since the time they began doing ILDKT (in other words, from 
the date of each center's first ILDKT; the earliest ILDKT was performed in September 
1997). Participating transplant centers provided the antibody strength prior to 
desensitization for ILDKT recipients, categorized as pre-transplant positive Luminex, 
negative flow crossmatch (PLNF), positive flow, negative cytotoxic crossmatch (PFNC), 
or positive cytotoxic crossmatch (PCC).  In some cases these were actual cell-based 
crossmatches, in others, they were virtual crossmatches based on semi-quantitative DSA 
strength on solid phase assays. Patients who had anti-HLA DSA and were also ABO-
incompatible (n=60, 5.8% of HLA-incompatible cohort) were considered part of the 
ILDKT population and were categorized based on the strength of the anti-HLA DSA as 
described above; a sensitivity analysis excluding these patients did not change any of our 
inferences.    
 
At Johns Hopkins reactions with test beads yielding mean fluorescence intensity (MFI) of 
>1000 have been considered Luminex positive.  The range of MFI values reported to 
result in a positive flow crossmatch is quite broad (2,000-20,000), and may be dependent 
on antibody class and specificity. PCC results have been associated with >10,000 MFI on 
phenotype panels. Significant variation in the results of solid phase assays within and 
especially between laboratories has been well characterized (59, 60).  Each laboratory 
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established its own MFI benchmarks that equate to the three crossmatch categories 
reported in this study. 
  
Data Linkage 
Data provided by transplant centers were linked to the SRTR for 1) ascertainment of risk 
factors (other than DSA strength) in a manner consistent with the PSRs, and 2) reliable 
ascertainment of outcomes (graft loss and death). The SRTR supplements death 
ascertainment through linkage to the Social Security Death Master File and death and 
graft loss ascertainment through linkage to data from the Centers for Medicare and 
Medicaid Services (CMS). The SRTR includes information on all donors, wait-listed 
transplant candidates, and transplant recipients in the U.S. provided by members of the 
Organ Procurement and Transplantation Network (OPTN), and has been well-described 
elsewhere (61).  The Health Resources and Services Administration, U.S. Department of 




All-cause graft loss was defined by the time between date of transplantation and either 
date of graft failure (marked by retransplantation, relisting, a return to dialysis, or death) 
or last date of follow-up with a functioning graft, with administrative censoring at the end 
of study. Death was defined as the time between date of transplantation and date of death 
or administrative end of the study. 
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Missing Data  
Because of changes from panel reactive antibody (PRA) to calculated PRA (CPRA) in 
2007, we combined all information available about PRA and/or CPRA, and those missing 
data (6.7%) were assumed to have the mean PRA/CPRA for ILDKT patients at their level 
of antibody strength.  ILDKT patients missing BMI or with BMI outside a realistic range 
of 14-50 kg/m
2
 (8.0%) were assumed to have a BMI that was the average for their gender 
and antibody strength.  All other variables were missing in <1% of ILDKT patients. 
Missingness in compatible recipients, serving as a comparison population, was treated 
using casewise deletion. 
 
Statistical Analysis 
Between-group characteristics were compared using chi-square test for categorical 
variables and ANOVA for continuous variables.  Mortality and graft loss were estimated 
using the Kaplan-Meier method and compared between groups using log-rank testing.  
Cox models were constructed to mirror (in terms of variable selection and functional 
form) the SRTR live donor kidney transplant PSR models for graft loss and mortality 
(49), with inclusion of DSA strength as an additional variable. Hazard ratios were 
obtained from the models for the time period up to 1-year post-transplant and after 1 year 
post-transplant, the former for its regulatory implications and the latter for its biologic 
and clinical relevance. A two-tailed p-value of <0.05 was considered statistically 
significant. Statistical analysis was performed using Stata 12.0 (StataCorp, College 
Station, Texas).  
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Regulatory Flagging Simulation 
To quantify the risk of CMS flagging that centers assume when they perform ILDKT, we 
conducted stochastic simulations of CMS center evaluations as previously described (62) 
for live donor kidney transplantation, using differing distributions of ILDKT use and risk. 
In other words, we simulated the likelihood of transplant centers being flagged by CMS 
for regulatory review, with an assumption (based on our previous survey (55)) that 30% 
of transplant centers performed no ILDKT, 40% of centers performed ILDKT for 5% of 
all of their live donor KT, 15% of centers performed ILDKT for 10% of all of their live 
donor KT, and the remaining 15% of centers performed ILDKT for 20% of all of their 
live donor KT. We conducted separate simulations using the all-cause graft loss risk 
estimates for PFNC and PCC based on the data censored at 1 year. Each simulation was 
run for 1000 iterations. Probability of flagging was calculated based on centers' 
proportion of ILDKT as a function of their overall live donor kidney transplant volume 
and centers' "risk quotient" (a number assigned to each center representing center quality, 
such that a center with average performance had a risk quotient of 1.0 and a center with 
50% higher risk had a risk quotient of 1.5). The risk quotient was randomly assigned and 
then centers were randomly assigned an ILDKT volume as a percent of overall live donor 
kidney transplant volume (0%, 5%, 10%, or 20%). The effect of ILDKT on flagging risk 






Across the 22 participating centers, 10,694 live donor kidney transplants were performed.  
Of these transplants, 1,025 (9.6%) were ILDKT, including 185 PLNF, 536 PFNC, and 
304 PCC transplants. ILDKT patients were more likely to be female (39.1% of 
compatible, 67.6% of PLNF, 68.1% of PFNC, and 64.8% of PCC patients; P<0.001), 
more likely to be covered by public insurance (38.6% of compatible, 42.7% of PLNF, 
52.4% of PFNC, and 59.5% of PCC patients; P<0.001), and were less frequently dialysis-
free at the time of transplantation (32.0% of compatible, 16.2% of PLNF, 13.2% of 
PFNC, and 8.2% of PCC patients; P<0.001) (Table 1). ILDKT patients were more likely 
to have previously received a transplant (14.7% of compatible, 36.8% of PLNF, 43.7% of 
PFNC, and 56.6% of PCC patients; P<0.001) and less likely to have undergone zero-
HLA-mismatch transplantation (9.1% of compatible, 2.2% of PLNF, 1.7% of PFNC, and 
1.3% of PCC patients; P<0.001). ILDKT patients also had substantially higher median 
peak PRA/CPRA values (0 [IQR: 0-7] for compatible, 51 [IQR: 18-82] for PLNF, 58 
[IQR: 13-93] for PFNC, and 85 [IQR: 50-98] for PCC patients).  
 
Graft Loss 
One-year unadjusted all-cause graft loss was 3.9%, 3.8%, 6.9%, and 19.4% for 
compatible, PLNF, PFNC, and PCC patients, respectively (P<0.001). Five-year 
unadjusted all-cause graft loss was 16.6%, 20.2%, 28.8%, and 39.9% for compatible, 
PLNF, PFNC, and PCC patients, respectively (Figure 1). Compared to compatible 
patients, PLNF patients had a similar adjusted risk of all-cause graft loss in the first year 
post-transplant (aHR=0.91; 95% CI: 0.43-1.94; P=0.81); however, PFNC (aHR=1.64; 
95% CI: 1.15-2.33; P=0.007) and PCC (aHR=5.01; 95% CI: 3.71-6.77; P<0.001) patients 
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had a significantly higher risk of all-cause graft loss in the first year post-transplant 
(Table 2). After the first year post-transplant, PLNF patients continued to have a similar 
adjusted risk of all-cause graft loss compared to compatible patients (aHR=1.20; 95% CI: 
0.83-1.75; P=0.33); however, PFNC (aHR=1.65; 95% CI: 1.36-1.99; P<0.001) and PCC 
(aHR=1.80; 95% CI: 1.42-2.29; P<0.001) patients continued to have a significantly 
higher risk of all-cause graft loss.  
 
Mortality 
One-year unadjusted mortality was 2.0%, 1.6%, 3.9%, and 8.9% for compatible, PLNF, 
PFNC, and PCC patients, respectively (P<0.001). Five-year unadjusted mortality was 
9.3%, 9.6%, 12.9%, and 19.1% for compatible, PLNF, PFNC, and PCC patients, 
respectively (Figure 2). Compared to compatible patients, PLNF patients had a similar 
risk of death in the first year post-transplant (aHR=0.83; 95% CI: 0.26-2.62; P=0.75); 
however, PFNC (aHR=2.04; 95% CI: 1.28-3.26; p=0.003) and PCC (aHR=4.59; 95% CI: 
2.98-7.07; P<0.001) patients had a significantly higher risk of death (Table 2). After the 
first year post-transplant, PLNF patients continued to have a similar adjusted risk of death 
compared to compatible patients (aHR=0.84; 95% CI: 0.48-1.48; P=0.55); however, 
PFNC (aHR=1.32; 95% CI: 1.02-1.70; P=0.037) and PCC (aHR=1.51; 95% CI: 1.13-
2.03; P<0.001) patients continued to have a significantly higher risk of death. 
 
Regulatory Flagging Simulation 
In the stochastic simulation, increased ILDKT volume and increased antibody strength 
were associated with significantly increased odds of flagging for further regulatory 
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scrutiny. Compared to centers of equal quality that performed no ILDKT, centers that 
performed 5%, 10%, or 20% PFNC ILDKT had a 1.19-fold (95% CI: 1.15-1.23), 1.33-
fold (95% CI: 1.28-1.39), and 1.73-fold (95% CI: 1.66-1.80) higher odds of CMS 
flagging, and centers which performed 5%, 10%, or 20% PCC ILDKT had a 2.22-fold 
(95% CI: 2.14-2.32), 4.09-fold (95% CI: 3.91-4.28), and 10.72-fold (10.27-11.18) higher 
odds of CMS flagging than their equal quality counterparts (Table 3). Different centers in 
the simulation have different "risk quotients"--a measure of center quality such that 
centers with a higher risk quotient have higher risk of graft loss within one year. A center 
with average performance (risk quotient=1) had a 0.5% chance of getting flagged if it 
performed no ILDKT, but an 8.5% chance of getting flagged if it performed 20% PCC 
ILDKT. A center with 50% higher risk of adverse outcomes (risk quotient=1.5) had a 
4.7% chance of getting flagged if it performed no ILDKT, but a 29.0% chance of getting 




In this 22-center United States study of ILDKT, increased anti-HLA DSA strength was 
associated with worse graft outcomes and higher mortality following live donor kidney 
transplantation.  Within the context of the SRTR models used by CMS, PLNF patients 
were similar to compatible patients in terms of all-cause graft loss and death. PFNC and 
PCC were associated with higher graft loss (aHR=1.64; 95% CI: 1.15-2.33; P=0.007 and 
aHR=5.01; 95% CI: 3.71-6.77; P<0.001, respectively). Our simulation of CMS 
regulatory flagging suggested that an increasing proportion of a center's ILDKT volume 
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led to significant increases in the odds of being flagged, even in the absence of poor 
performance. Centers that performed PFNC ILDKT as 20 percent of their volume were 
expected to have a 1.73-fold (95% CI: 1.66-1.80) higher odds of being flagged, and those 
that performed PCC ILDKT as 20 percent of their volume were expected to have a 10.72-
fold (95% CI: 10.27-11.18) higher odds of being flagged.  
 
The ILDKT literature has thus far been based on single-center data with insufficient 
sample sizes to quantify risk in a precise, generalizable manner (15, 34, 56-58, 63-79). In 
addition, most of these single-center studies have been descriptive, with absent or limited 
control groups. Our findings of increased risk of graft loss and death with increasing level 
of antibody strength, are consistent with previous single-center studies (20, 80). Other 
studies have compared the outcomes of ILDKT to compatible live donor kidney 
transplantation, albeit with much less power to adjust for multiple confounding factors 
(35, 56-58). Haririan and colleagues found that 41 patients with a positive flow 
crossmatch had a 2.6-fold higher risk of graft loss compared to patients matched on 
gender, race, age, prior kidney transplant, and year of transplantation. The Mayo Clinic 
group reported a 5-year death-censored graft survival rate of 70.7% in 102 ILDKT 
patients, compared to 96.7% in compatible recipients matched for age and sex. They also 
found that PCC patients had a higher incidence of graft loss than PFNC patients at 1 year, 
although that difference was not statistically significant by 5 years.  
 
Our study found no difference in patient or graft survival outcomes for PLNF patients 
compared to compatible patients. In a retrospective study of deceased and live donor 
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kidney transplants, Gibney and colleagues reported that patients with DSA detected by 
Luminex but negative by cytotoxic crossmatch had worse graft survival but similar 
patient survival compared to compatible kidney transplant recipients (81). However, the 
authors did not report flow cytometric crossmatch results on these patients, so it remains 
unclear if the difference in graft survival in their study was because some of the patients 
were actually PFNC. Consistent with our findings, Loupy and colleagues showed 
equivalent graft and patient outcomes among recipients of deceased donor kidneys with 
pre-transplant DSA detected by solid-phase assay compared to those without DSA (82). 
However, the wide confidence intervals for PLNF estimates suggest that the risk 
associated with this strength of anti-HLA antibody remains incompletely characterized. 
 
The strengths of this study include its multicenter design (22 centers), large sample size 
(n=10,694), and control group (compatible kidney transplant recipients at the same center, 
adjusted for SRTR variables, with the statistical power to accommodate all of these 
variables in a regression model). Participating centers represent more than one-fifth of the 
2011 U.S. live donor kidney transplant volume, permitting quantification of the risk 
associated with increasing antibody strength without the limitations associated with 
existing single-center reports.  
 
Limitations include heterogeneity across the 22 centers with respect to HLA antibody 
testing and interpretations of these assays, especially when comparing DSA strength (83).  
Significant variation exists in the management of interfering agents such as auto-antibody 
and therapeutic agents in solid phase immunoassays and their subsequent interpretation 
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(84). Even under tightly controlled circumstances, there is still significant variability in 
the assessment of antibody strength (85). Centers have their own thresholds of mean 
fluorescence intensity and mean channel shifts that constitute a positive crossmatch. For 
cell-based assays, there is significant center-level variation in the conduct and materials 
of the crossmatch, and also in the threshold for positivity (86). However, our study design 
accounted for this in two ways. First, we asked each center to classify each patient as 
PLNF, PFNC, and PCC in order to find a common classification system and allow for the 
development of the largest cohort of ILDKT patients to date. Second, we only included 
patients who underwent desensitization, so as to only study those that the centers felt had 
sufficiently strong DSA to warrant the risks and costs of desensitization. Desensitization 
strategies, treatment of antibody-mediated rejection, and management of persistent post-
operative DSA vary across centers. This study was not designed to assess these 
differences, nor to determine the best management of these clinical challenges; however, 
it does provide a real-world snapshot of the aggregate outcomes that result from these 
various practices.   
 
This multicenter study of ILDKT quantifies the risk for both patients and transplant 
centers associated with desensitizing and transplanting patients with pre-existing DSA.  
Even after adjusting for all of the variables in the PSRs, there is a 1.64 and 5.01-fold 
increase in the risk of graft loss and a 2.04 and 4.59-fold increase in the risk of death for 
PFNC and PCC patients, respectively, in the first year post-transplant. PFNC and PCC 
patients continued to have elevated risk of graft loss and death after the first year post-
transplant compared to compatible patients. For centers that perform 20% PFNC and 
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20% PCC as percentages of their overall live donor kidney transplant volume, there is a 
1.73 and 10.72-fold increase in the odds of flagging by CMS compared to centers of 
equal quality that do not perform ILDKT. These findings warn of significant regulatory 
risk associated with ILDKT. Confirmation of our previous single-center demonstration of 
ILDKT survival benefit (15) on a multi-center level is necessary to better inform whether 
the increased regulatory scrutiny is justified or biased against beneficial treatment based 
on best evidence. The outcomes also serve as a benchmark for the assessment of the 
efficacy of new innovations and best practices for the relatively young field of HLA-
incompatible kidney transplantation. 
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Mean Age at Transplant (SD) 47.8 (13.8) 45.4 (12.7) 45.5 (12.6) 43.8 (13.2) 0.17 
Female Sex 39.1% 67.6% 68.1% 64.8% 0.006 
Recipient Race     0.001 
White 68.3% 64.9% 67.7% 73.4%  
Black 15.2% 17.3% 18.7% 11.8%  
Hispanic/Latino 10.9% 9.2% 9.1% 11.8%  
Asian 4.7% 7.6% 3.0% 2.6%  
Public Insurance 38.6% 42.7% 52.4% 59.5% 0.001 
Prior Transplant 14.7% 36.8% 43.7% 56.6% <0.001 
Zero HLA Mismatch 9.1% 2.2% 1.7% 1.3% 0.89 
Median Peak PRA/CPRA 
(IQR)  
0 (0-7) 51 (18-82) 57.5 (14-93) 85 (50-98) <0.001 
Mean Recipient BMI (SD) 27.5 (5.8) 26.2 (5.4) 26.6 (6.2) 25.6 (5.5) 0.10 
ESRD Diagnosis     0.073 
Glomerular Disease 27.7% 36.2% 36.7% 35.2%  
Diabetes 23.5% 22.2% 14.2% 10.2%  
Hypertension 19.2% 7.6% 12.5% 15.8%  
Polycystic Kidney Disease 10.4% 10.3% 9.5% 8.2%  
Vascular Disease 1.4% 1.9% 1.7% 2.0%  
Other 17.8% 22.7% 25.4% 28.6%  
Time on Dialysis Prior to 
Recent Transplant 
    <0.001 
Preemptive 32.0% 16.2% 13.2% 8.2%  
<2 years 41.8% 28.6% 28.5% 16.8%  
2-6 years 14.4% 22.2% 18.1% 19.1%  
>6 years 11.9% 33.0% 40.1% 55.9%  
Recipient HCV 3.7% 8.1% 6.7% 5.3% 0.50 
Mean Donor Age (SD) 42.0 (11.7) 41.6 (11.3) 40.5 (11.7) 40.5 (11.8) 0.57 
Living Related Donor 42.8% 55.1% 45.7% 43.4% 0.04 
Donor Race     <0.001 
White 70.9% 69.2% 68.3% 76.3%  
Black 13.5% 14.0% 17.5% 8.5%  
Hispanic/Latino 10.6% 8.1% 9.7% 11.2%  
Asian 4.0% 8.1% 2.8% 3.3%  
 
SD=standard deviation; PRA=panel reactive antibody; CPRA=calculated panel reactive antibody; 




Table 2. Adjusted Risk of All-Cause Graft Loss and Mortality in the First Year Post-







































































Risk was adjusted based on the variables in the Scientific Registry of Transplant Recipients 1 year 
adjustment models for graft loss and mortality.  
aHR=adjusted hazard ratio 






Table 3.  Effect of Incompatible Live Donor Kidney Transplantation on Risk of Flagging 
by Centers for Medicare & Medicaid Studies in a Simulation.  
 
 Odds Ratio of Regulatory Flagging 







No ILDKT Reference Reference 
5 % ILDKT 1.19 (1.15-1.23) 2.22 (2.14-2.32) 
10% ILDKT 1.33 (1.28-1.39) 4.09 (3.91-4.28) 
20% ILDKT 1.73 (1.66-1.80) 10.72 (10.27-11.18) 
 
This simulation, run 1000 times, estimates the likelihood of transplant centers being flagged by CMS for 
regulatory review, with an assumption that 30% of transplant centers performed no ILDKT, 40% of centers 
performed ILDKT for 5% of all of their live donor KT, 15% of centers performed ILDKT for 10% of all of 
their live donor KT, and the remaining 15% of centers performed ILDKT for 20% of all of their live donor 
KT. We conducted separate simulations using the all-cause graft loss risk estimates for PFNC and PCC. 
Probability of flagging was calculated based on centers' proportion of ILDKT as a function of their overall 
live donor kidney transplant volume and centers' "risk quotient" (a number assigned to each center 
representing center quality, such that a center with average performance had a risk quotient of 1.0 and a 
center with 50% higher risk had a risk quotient of 1.5). The risk quotient was randomly assigned and then 
centers were randomly assigned an ILDKT volume as a percent of overall live donor kidney transplant 
volume (0%, 5%, 10%, or 15%). The effect of ILDKT on flagging risk was evaluated using logistic 
regression. 
Compared to centers which performed no ILDKT, centers of equal quality which performed 5%, 10%, or 
20% PFNC ILDKT had 1.19-fold, 1.33-fold, and 1.73-fold higher odds of CMS flagging, respectively, in a 
logistic regression model. Centers which performed 5%, 10%, or 20% PCC ILDKT had 2.22-fold, 4.09-
fold, and 10.72-fold higher odds of CMS flagging, respectively. All p values are < 0.001. 
 
ILDKT=incompatible live donor kidney transplantation; PFNC=positive flow, negative cytotoxic 
















PCC=positive cytotoxic crossmatch; PFNC=positive flow, negative cytotoxic crossmatch; PLNF=positive 























PCC=positive cytotoxic crossmatch; PFNC=positive flow, negative cytotoxic crossmatch; PLNF=positive 










Figure 3. The Effect of Incompatible Live Donor Kidney Transplantation on Risk of 




Different centers in the simulation have different "risk quotients" – a measure of center quality such that 
centers with a higher risk quotient have higher risk of graft loss within one year. A center with average 
performance (risk quotient=1) had a 0.5% chance of getting flagged if it performed no ILDKT, but an 8.5% 
chance of getting flagged if it performed 20% PCC ILDKT. A center with 50% higher risk of adverse 
outcomes (risk quotient=1.5) had a 4.7% chance of getting flagged if it performed no ILDKT, but a 29.0% 
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While antibody-mediated rejection (AMR) has been implicated in reducing graft survival, 
the magnitude of this effect is unclear, and it remains unknown if this effect is 
homogeneous across donor types (deceased/live), antibody types (HLA/ABO), and 
presentation (clinical/subclinical). We compared 219 patients with biopsy-proven AMR 
to controls matched on HLA-compatibility, ABO-compatibility, donor type, prior 
transplant, PRA, age, and transplant year. Graft loss in AMR patients at 1 and 5 years 
was 14.2% and 28.9%, versus 2.0% and 8.0% in matched controls (P<0.001), a finding 
confirmed by propensity score-matching. AMR was independently associated with 4.61-
fold higher graft loss (95% CI: 3.19-6.68, p<0.001) compared to matched controls, 
although this effect was heterogeneous when stratified by HLA-compatible deceased 
donor (HR=4.73;95%CI:1.57-14.26;P=0.006), HLA-incompatible deceased donor 
(HR=2.39;95%CI:1.10-5.19;P=0.028), HLA-compatible live donor (no AMR patients 
had graft loss), ABO-incompatible live donor (HR=6.13;95%CI:0.55-67.70;P=0.14), and 
HLA-incompatible live donor (HR=6.29;95%CI:3.81-10.39;P<0.001) transplant. A 
subclinical AMR presentation was independently associated with 2.35-fold higher graft 
loss (95%CI:1.30-4.25;P=0.005) compared to matched non-AMR controls. AMR, even 
without a clinical presentation, substantially increases graft loss, particularly in deceased 
donor and HLA-incompatible live donor recipients. Aggressive prevention, surveillance, 







Over 30% of the kidney transplant waitlist is comprised of sensitized patients 
(PRA>20%) (87). In an effort to transplant these vulnerable patients, advances in 
desensitization protocols and kidney paired donation have promoted the widespread 
adoption of incompatible kidney transplantation at centers across the United States (12, 
14, 15, 88). While antibody-mediated rejection (AMR) occurs in approximately 5% of 
compatible kidney transplants, the incidence seems to be significantly higher in 
incompatible kidney transplant recipients, as high as 40% in some reports (80, 89, 90). As 
incompatible kidney transplantation and re-transplantation become more common (91), 
the incidence of antibody-mediated rejection (AMR) can only be expected to increase. 
 
AMR has long been suspected to threaten graft survival. However, the magnitude of this 
effect is unclear; estimates of the risk of graft loss range from 1.53 (95% CI: 1.21-1.91) 
to 4.58 (95% CI: 1.75-12.00) (92, 93). Furthermore, it remains unknown, both 
epidemiologically and mechanistically, if AMR differentially affects graft outcomes 
depending upon donor compatibility and donor type (deceased versus live donor). Indeed, 
the 2013 Banff Conference on Allograft Pathology reported that, for the first time, there 
will be a Banff Working Group formed to evaluate possible differences between non-
sensitized patients who develop AMR and patients requiring desensitization who develop 
AMR (39). Finally, studies to date have suggested that patients with a subclinical 
presentation of AMR have poorer graft function and worse pathological findings on 
subsequent allograft biopsies (46, 82), though an association between subclinical AMR 
and increased graft loss has yet to be explored. 
 34 
 
The objective of this study was to understand the risk of allograft loss associated with 
AMR using a well-defined set of clinicopathologic criteria. We also sought to quantify 
the risk of graft loss following AMR by the type of transplant (e.g., HLA-compatible 
deceased donor, HLA-incompatible deceased donor, HLA-compatible live donor, ABO-
incompatible live donor, HLA-incompatible live donor) performed as well as its 





We studied all adult (>18 years of age), kidney-only transplants performed at the Johns 
Hopkins Hospital from January 2000 through December 2012 (n=2,317). HLA-
incompatible live donor recipients were defined as those who had anti-HLA DSA at a 
strength requiring perioperative desensitization therapy. Deceased donor HLA-
incompatible recipients were those who had the presence of anti-HLA DSA identified at 
the time of transplant, but with a negative cytotoxic crossmatch. Patients who were ABO-
incompatible with their donor and also had anti-HLA DSA were studied as members of 
the HLA-incompatible live donor group. This study was approved by the Johns Hopkins 




Because of OPTN policy changes from PRA to CPRA in 2007, we combined all 
information available about PRA and/or CPRA, and those missing data (2.8%) were 
imputed to have the mean PRA/CPRA for patients of their same transplant type. 
 
Performance of Biopsies: 
Ultrasound-guided needle allograft biopsies were performed as previously described (94). 
Occasionally, biopsies were performed during an open re-operation under direct 
visualization. C4d staining was performed on frozen tissue using indirect 
immunofluorescence with anti-human C4d antibody (Quidel, San Diego, CA) at 1:40 
dilution followed by secondary antibody (fluorescein isothiocyanate–conjugated goat 
anti-mouse IgG; Jackson Immunoresearch Laboratories, West Grove, PA) or on paraffin-
embedded tissue sections using a rabbit polyclonal anti-human antibody (American, 
Pfungstadt, Germany) at a 1:50 dilution, in concert with a biotin-free polymer detection 
system (Leica, Wetzlar, Germany). 
 
Diagnosis of AMR: 
The diagnosis of AMR occurring in the first year post-transplant was based on the 2013 
international Banff Classification Criteria (39) and defined as the presence of circulating 
DSA and either: 1) peritubular capillary staining of C4d and at least one of the following: 
ptc score>0, g score>0, acute thrombotic microangiopathy in the absence of any other 
cause, or other features consistent with AMR (endothelial injury, fibrin thrombi, 
microinfarctions, interstitial hemorrhage), or 2) absence of capillary staining of C4d and 
the presence of ptc>0 and g>0 or ptc>0 or g>0 and acute thrombotic microangiopathy, in 
 36 
the absence of any other cause of thrombotic microangiopathy. Index episodes of AMR 
were also noted to be clinical or subclinical. Clinical episodes of AMR were defined as 
those that had evidence of graft dysfunction, manifested as oliguria/anuria, an increase in 
serum creatinine by >20% from baseline, treatment of cell-mediated rejection and/or 
thrombotic microangiopathy within the two prior weeks, or new onset proteinuria.  
 
Matched Controls Selection 
Patients who developed AMR were matched to those who did not develop AMR using 
iterative expanding radius matching as previously described (15, 95, 96). AMR patients 
were matched in a 1:3 ratio on HLA-compatibility, ABO-compatibility, donor type 
(deceased versus live), history of previous transplant, peak PRA/CPRA, age at transplant, 
and year of transplant.  
 
Outcome Ascertainment 
Death-censored graft survival (DCGS) was defined as the time between date of transplant 
and either date of graft failure (marked by retransplantation, relisting, or a return to 
dialysis) or last date of follow-up with a functioning graft, censoring for death and 
administrative end of study. Death and graft failure ascertainment were augmented 
through linkage with the Social Security Death Master File and the Centers for Medicare 
and Medicaid Services by the Scientific Registry of Transplant Recipients (SRTR). The 
SRTR includes information on all donors, wait-listed transplant candidates, and 
transplant recipients in the U.S. provided by members of the Organ Procurement and 
Transplantation Network (OPTN), and has been well-described elsewhere (97). The 
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Health Resources and Services Administration (HRSA), U.S. Department of Health and 
Human Services provides oversight to the activities of the OPTN and SRTR contractors.  
 
Statistical Analysis 
Between-group characteristics were compared using chi-square test for categorical 
variables, ANOVA for normally distributed continuous variables, and the Wilcoxon rank 
sum test for non-normally distributed continuous variables. Death-censored graft survival 
was estimated using the Kaplan-Meier method and compared between groups using log-
rank testing and Cox models. Proportional hazards assumptions were confirmed by visual 
inspection of complimentary log-log plots. Separate Cox models were performed by the 
type of transplant (HLA-compatible/incompatible live donor transplant, HLA-
compatible/incompatible deceased donor transplant, ABO-incompatible live donor 
transplant). Analyses were performed using Stata 12.1/SE (Stata Corp, College Station, 
TX). A two-tailed p-value less than 0.05 was considered statistically significant.  
 
Propensity Score Analysis 
As a sensitivity analysis, AMR patients were compared with non-AMR controls matched 
on propensity for developing AMR. Propensity scores were generated using R (R 
Foundation for Statistical Computing, Vienna, Austria) with random forest methods, and 
1:1 matches were assigned using nearest neighbor matching. Subsequent analyses were 
performed with Stata. Graft survival was estimated using the Kaplan-Meier method and 
compared between AMR patients and propensity score-matched non-AMR controls using 
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log-rank testing and Cox models. There was no difference in the inferences of the 





Of 2,316 patients who underwent kidney-only transplantation during the study period, 
219 developed biopsy-proven AMR (9.5%). AMR patients were more frequently female 
(58.9% versus 42.9%), had a higher median peak PRA/CPRA (80 versus 2), spent more 
time on dialysis prior to the transplant (56.2% on dialysis >6 years versus 18.1%), and 
were more likely to have undergone a previous transplant (55.2% versus 16.7%) (Table 
1). AMR patients were more likely have been the recipients of HLA-incompatible live 
donor transplants (63.0% versus 7.6%), ABO-incompatible live donor transplants (16.4% 
versus 4.2%), and HLA-incompatible deceased donor transplants (19.6% versus 2.6%).  
 
AMR Incidence 
The incidence of AMR was 1.9% in HLA-compatible deceased donor transplant 
recipients, 44.3% in HLA-incompatible deceased donor transplant recipients, 0.7% in 
HLA-compatible live donor transplant recipients, 14.8% in ABO-incompatible live donor 
transplant recipients, and 45.1% in HLA-incompatible live donor transplant recipients. 
 
Death-Censored Graft Survival 
Death-censored graft survival in AMR patients was 85.8% at 1 year and 71.1% at 5 years, 
98.0% and 92.0% for matched non-AMR controls (P<0.001) (Figure 1, Table 2).  
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Graft Loss by Transplant Type 
Recipients who developed AMR had a 4.61-fold higher risk of graft loss (95% CI: 3.19-
6.68; P<0.001) (Table 3A) when compared to matched controls. This risk varied by donor 
type and compatibility, with 4.73-fold higher risk (95% CI: 1.57-14.26; P=0.006) in 
HLA-compatible deceased donor recipients, 2.39-fold higher risk (95% CI: 1.10-5.19; 
P=0.028) in HLA-incompatible deceased donor recipients, 6.13-fold higher risk (95% CI: 
0.55-67.70; P=0.14) in ABO-incompatible live donor recipients, and 6.29-fold higher risk 
(95% CI: 3.81-10.39; P<0.001) in HLA-incompatible live donor recipients. No HLA-
compatible live donor recipients with AMR experienced graft loss.  
 
Subclinical Presentations of Antibody-Mediated Rejection 
Of patients who developed AMR, 39.3% had a subclinical presentation of AMR at the 
time of their AMR-defining biopsy. By transplant type, 25.0% of HLA-compatible 
deceased donor recipients, 32.6% of HLA-incompatible deceased donor recipients, 
50.0% of HLA-compatible live donor recipients, 50.0% of ABO-incompatible live donor 
recipients, and 42.0% of HLA-incompatible live donor recipients who had AMR had 
subclinical presentations of AMR (Table 3B).  
 
Graft Outcomes in Subclinical AMR 
Death-censored graft survival in subclinical AMR patients was 95.1% at 1 year and 
75.5% at 5 years, versus 96.3% and 89.2% for controls matched to the subclinical 
patients (P=0.004) (Figure 2), and 79.8% at 1 year and 68.0% at 5 years for patients with 
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a clinical presentation of AMR (Figure 3). The risk of graft loss for patients developing 
subclinical AMR was 2.35-fold (95% CI: 1.30-4.25; P=0.005) higher than for matched 
controls without AMR. The risk of graft loss for patients with a clinical presentation of 
AMR was 1.66-fold (95% CI: 0.96-2.85; P=0.067) higher than for patients with a 




In this single-center study of 219-patients who developed biopsy-proven AMR consistent 
with 2013 Banff diagnostic criteria, we found that AMR was associated with an overall 
4.61-fold (95% CI: 3.19-6.68; P<0.001) increase in the risk of graft loss. Specifically, the 
risk of graft loss for AMR patients was 4.73-fold (95% CI: 1.57-14.26; P=0.006) higher 
in HLA-compatible deceased donor recipients, 2.39-fold (95% CI: 1.10-5.19; P=0.028) 
higher in HLA-incompatible deceased donor recipients, 6.13-fold (95% CI: 0.55-67.70; 
P=0.14) higher in ABO-incompatible live donor recipients, and 6.29-fold (95% CI: 3.81-
10.39; P<0.001) higher in HLA-incompatible live donor recipients. No HLA-compatible 
live donor recipients with AMR experienced graft loss. The risk of graft loss for patients 
with a subclinical presentation of AMR was 2.35-fold (95% CI: 1.30-4.25; P=0.005) 
higher than for matched controls without AMR. In turn, the risk of graft loss for patients 
with a clinical presentation of AMR was 1.66-fold (95% CI: 0.96-2.85; P=0.067) higher 
than for patients with a subclinical presentation of AMR. 
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The rare occurrence of AMR in HLA-compatible recipients (0.7% live donor and 1.9% 
deceased donor) in our study is consistent with other single-center studies (98, 99). For 
example, Everly et al. reported a 1.8% and 1.5% incidence of AMR in HLA-compatible 
live and deceased donors. The incidences of AMR among deceased donor recipients 
(44.3% HLA-incompatible and 1.9% HLA-compatible) were consistent with incidences 
of 43-54% and 5% reported in the literature (44, 100). The high incidence of AMR in 
HLA-incompatible live donor recipients (46.5%) is also consistent with the 41-53% 
incidence reported by others (35, 57, 70). AMR occurred in 14.8% of our ABO-
incompatible live donor recipients, compared to 40% reported by Fidler and colleagues 
(101), although this is likely related to the fact that we defined the ABO-incompatible 
cohort to be purely ABO-incompatible, i.e. ABO-incompatible transplants with anti-HLA 
DSA were categorized as HLA-incompatible live donor transplants. When all ABO-
incompatible transplants were considered, irrespective of anti-HLA DSA, our AMR 
incidence in ABO-incompatible recipients was a more similar 28.8%. Toki, et al., 
reported a 33% incidence of AMR in the first 3 months post-transplant in their ABO-
incompatible live donor recipients (102). 
 
Our findings of increased graft loss following AMR consolidate evidence of this causal 
pathway from several other studies. Loupy and colleagues reported that glomerular and 
peritubular inflammation, transplant glomerulopathy, and post-transplant C1q-binding 
DSA (pathologic and immunologic factors of AMR) on 1-year protocol biopsies were 
independently associated with graft loss (47). Lefaucheur et al. reported a 4.1-fold (95% 
CI: 2.2-7.7) higher risk of graft loss in HLA-incompatible deceased donor recipients who 
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developed AMR, consistent with but higher than our finding of a 2.39-fold (95% CI: 
1.10-5.19) higher risk (103). Couzi and colleagues reported a trend toward worse graft 
survival in this population as well (100). Dunn and colleagues also demonstrated a 2.9-
fold increase in the risk of graft loss for live and deceased donor recipients with pre-
transplant DSA (35). In a study of HLA-incompatible live donor recipients, Gloor and 
colleagues reported a nearly 3-fold increase in graft loss in AMR patients,, compared to 
our finding of a 6.3-fold increase in the risk of graft loss (57). Among ABO-incompatible 
live donor recipients, however, Fidler, et al., did not find increased graft loss following 
AMR, nor did they find an increased incidence of chronic allograft nephropathy on 1-
year protocol biopsies (101). While Toki, et al., reported significantly worse graft 
survival in ABO-incompatible live donor AMR patients, all of the patients who 
experienced graft loss also had pre-transplant anti-HLA DSA (102), so these inferences 
are not generalizable to pure ABO-incompatibility. We did not detect a statistically 
significant difference in the risk of graft loss for ABO-incompatible patients who develop 
AMR (HR: 6.13; 95% CI: 0.55-67.70); however, the wide confidence interval for this 
estimate suggests that the risk associated with AMR in ABO-incompatible recipients 
remains incompletely characterized. 
 
Our finding of subclinical AMR associated with worse graft survival is novel, and 
consistent with previous findings of worse graft function and histologic findings in 
patients who previously had subclinical AMR. Our group has previously reported that 
subclinical AMR is associated with the development of chronic allograft nephropathy 
(46). Loupy and colleagues, in a study of HLA-incompatible deceased donor recipients, 
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reported a number of adverse associations with subclinical AMR, including lower 
glomerular filtration rate, higher serum creatinine, and more peritubular capillaritis, C4d 
deposition, and transplant glomerulopathy on biopsy, and worse all-cause graft survival 
at 4 years post-transplant (82).  
 
Strengths of this investigation include the timely, rigorous criteria for AMR consistent 
with the Banff 2013 criteria and the fact that this is the largest known cohort of patients 
with AMR (39). Limitations of this study include the possibility of misclassification of 
AMR, particularly in the event of subclinical AMR, which is less likely to prompt a for-
cause biopsy. However, such cases of AMR (that do not result in clinical renal 
dysfunction) are were likely to be the least harmful to graft survival, so this 
misclassification, if present, would likely bias towards the null, rendering our estimates 
of the risk of graft loss conservative. Furthermore, we performed protocol biopsies at 1, 3, 
6, and 12 months following ABO- and HLA-incompatible live donor transplants, but not 
routinely after deceased donor transplants or compatible live donor transplants, 
introducing possible ascertainment bias. Finally, because this study includes patients 
from a single institution, there may be some limits to external validity (i.e. 
generalizability to the general transplant population).  
 
CONCLUSION:  
The development of AMR is associated with a significantly higher incidence of allograft 
loss, although the effects of AMR differ by transplant type. HLA-compatible live donor 
recipients who develop AMR do not have a higher risk of graft loss compared to their 
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counterparts who do not develop AMR, and the risk for recipients of ABO-incompatible 
transplants remains inconclusive. However, deceased donor (both HLA-compatible and 
HLA-incompatible) and HLA-incompatible live donor recipients do have significantly 
higher risks of graft loss following AMR. Subclinical AMR also poses a threat to graft 
survival. These data highlight the need for strategies to prevent and aggressively treat 
AMR, as well as performance of protocol biopsies in high-risk patients.  
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 Table 1. Patient Characteristics of the Overall Cohort, the Antibody-Mediated Rejection 















TRANSPLANT TYPE      
Deceased Donor 48.7% 50.7% 28.8% 25.7% 0.4 
HLA-Incompatible 4.2% 2.6% 19.6% 16.4% 0.3 
Live Donor 51.3% 49.3% 71.2% 74.3% 0.4 
ABO-Incompatible 5.4% 4.2% 16.4% 12.6% 0.1 





   
Age at Transplant (SD) 50.3 (14.2) 50.8 (14.2) 46.0 (13.4) 46.0 (11.9) 0.8 
Female 44.4% 42.9% 58.9% 59.7% 0.8 
African-American 33.8% 34.8% 24.7% 25.4% 0.8 
Public Insurance 47.1% 45.2% 65.7% 52.2% 0.002 
BMI (SD) 27.3 (6.0) 27.5 (6.0) 25.9 (6.1) 26.4 (6.0) 0.3 
Cause of ESRD      
Glomerular Diseases 25.3% 23.9% 38.4% 34.2% 0.3 
Diabetes Mellitus 17.8% 18.6% 10.3% 11.0% 0.6 
Hypertensive Nephrosclerosis 29.9% 31.1% 21.0% 17.2% 0.7 
Polycystic Kidney Disease 9.8% 9.8% 9.0% 13.1% 0.2 




0.5% 0.9% 0.02 
Other or Missing (includes 
Tubular and Congenital) 
16.3% 
15.8% 
23.3% 21.3% 0.9 
Peak PRA/CPRA (IQR) 4 (0-100) 2 (0-33) 80 (23-100) 92 (70-100) 0.9 
Previous Transplant 20.4% 16.7% 55.2% 55.1% 1.0 
Zero HLA-mismatch 7.2% 7.9% 4.1% 0.9% 0.02 




  0.4 
Preemptive 16.7% 17.9% 5.9% 9.4%  
<2years 30.2% 31.9% 14.2% 15.4%  
2-6 years 31.3% 32.1% 23.7% 23.6%  
>6 years 21.7% 18.1% 56.2% 51.6%  
Donor Age (SD) 40.8 (14.6) 40.7 (14.8) 42.2 (12.9) 40.3 (14.0) 0.08 
 
*Refers to the statistical test that tested the difference between AMR patients and matched controls. 
 
‡ Patients who developed AMR were matched in a 1:3 ratio on HLA-compatibility, ABO-compatibility, 
donor type (deceased versus live), history of previous transplant, peak panel-reactive antibody/calculated 
panel reactive antibody, age at transplant, and year of transplant to patients who did not develop AMR. 
 
AMR=antibody-mediated rejection, SD=standard deviation, BMI=body mass index, ESRD=end stage renal 




Table 2. Estimates of Death-Censored Graft Survival 
 
 
Death-Censored Graft Survival 
P-
Value 
1 Year  
(95% Confidence Interval) 
5 Year  
(95% Confidence Interval) 
AMR 






































* Patients who developed AMR were matched in a 1:3 ratio on HLA-compatibility, ABO-compatibility, 
donor type (deceased versus live), history of previous transplant, peak panel-reactive antibody/calculated 
panel reactive antibody, age at transplant, and year of transplant to patients who did not develop AMR. 
 
 Refers to the statistical test between AMR patients and non-AMR matched controls. 
 
§ Refers to the statistical test between AMR patients and non-AMR propensity score matched controls. 
 
‡ Clinical episodes of AMR were distinguished from subclinical episodes of AMR by the presence of 
evidence of graft dysfunction, manifested as oliguria/anuria, an increase in serum creatinine by >20% from 
baseline, treatment of cell-mediated rejection and/or thrombotic microangiopathy within the two prior 
weeks, or new onset proteinuria. 
 
 Refers to the statistical test between AMR patients with a clinical presentation and AMR patients with a 
subclinical presentation. 
 
 Patients who developed subclinical AMR were matched in a 1:3 ratio on HLA-compatibility, ABO-
compatibility, donor type (deceased versus live), history of previous transplant, peak panel-reactive 
antibody/calculated panel reactive antibody, age at transplant, and year of transplant to patients who did not 
develop AMR. 
 
AMR=antibody-mediated rejection  
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Table 3A. Antibody-Mediated Rejection Risk of Graft Loss, by Transplant Type 
 
Transplant Type Hazard Ratio‡ P-value 
Deceased Donor: HLA-Compatible 4.73 (1.57-14.26) 0.006 
Deceased Donor: HLA-Incompatible 2.39 (1.10-5.19) 0.028 
Live Donor: HLA-Compatible  NA§ -- 
Live donor: ABO-Incompatible 6.13 (0.55-67.70) 0.1 
Live Donor: HLA-Incompatible 6.29 (3.81-10.39) 0.001 
Overall 4.61 (3.19-6.68) <0.001 
 
Table 3B. Antibody-Mediated Rejection Incidence and Presentation 
 
Transplant Type 









Deceased Donor: HLA-Compatible 1.9% 1.5% 0.5% 
Deceased Donor: HLA-Incompatible 44.3% 29.9% 14.4% 
Live Donor: HLA-Compatible 0.7% 0.4% 0.4% 
Live donor: ABO-Incompatible 14.8% 7.4% 7.4% 
Live Donor: HLA-Incompatible 46.5% 26.9% 19.5% 
Overall 9.4% 5.7% 3.7% 
 
The diagnosis of antibody-mediated rejection (AMR) occurring in the first year post-transplantation was 
based on the 2013 international Banff Classification Criteria (39) and defined as the presence of circulating 
donor-specific antibody and either: 1) peritubular capillary staining of C4d and at least one of the 
following: ptc score>0, g score>0, acute thrombotic microangiopathy in the absence of any other cause, or 
other features consistent with AMR (endothelial injury, fibrin thrombi, microinfarctions, interstitial 
hemorrhage), or 2) absence of capillary staining of C4d and the presence of ptc>0 and g>0 or ptc>0 or g>0 
and acute thrombotic microangiopathy, in the absence of any other cause of thrombotic microangiopathy. 
Patients who developed AMR were matched in a 1:3 ratio on HLA-compatibility, ABO-compatibility, 
donor type (deceased versus live), history of previous transplant, peak panel-reactive antibody/calculated 
panel reactive antibody, age at transplant, and year of transplant to patients who did not develop AMR.  
 
* Clinical episodes of AMR were distinguished from subclinical episodes of AMR by the presence of 
evidence of graft dysfunction, manifested as oliguria/anuria, an increase in serum creatinine by >20% from 
baseline, treatment of cell-mediated rejection and/or thrombotic microangiopathy within the two prior 
weeks, or new onset proteinuria. 
 
‡ Refers to hazard ratio comparing AMR patients of a transplant type with patients of the same transplant 
type who did not develop AMR.  
 
§ Hazard ratio could not be calculated as no HLA-compatible live donor recipients with AMR had a graft 
loss during the study period.  
 
 Patients who were ABO-incompatible with their donor and also had anti-HLA donor-specific antibody 
were considered to be members of the HLA-incompatible live donor group (n=76; 13.8% of the HLA-
incompatible live donor recipient population). 
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The diagnosis of antibody-mediated rejection (AMR) occurring in the first year post-transplantation was 
based on the 2013 international Banff Classification Criteria (39) and defined as the presence of circulating 
donor-specific antibody and either: 1) peritubular capillary staining of C4d and at least one of the 
following: ptc score>0, g score>0, acute thrombotic microangiopathy in the absence of any other cause, or 
other features consistent with AMR (endothelial injury, fibrin thrombi, microinfarctions, interstitial 
hemorrhage), or 2) absence of capillary staining of C4d and the presence of ptc>0 and g>0 or ptc>0 or g>0 
and acute thrombotic microangiopathy, in the absence of any other cause of thrombotic microangiopathy.  
 
Patients who developed AMR were matched in a 1:3 ratio on HLA-compatibility, ABO-compatibility, 
donor type (deceased versus live), history of previous transplant, peak panel-reactive antibody/calculated 
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The diagnosis of antibody-mediated rejection (AMR) occurring in the first year post-transplantation was 
based on the 2013 international Banff Classification Criteria (39) and defined as the presence of circulating 
donor-specific antibody and either: 1) peritubular capillary staining of C4d and at least one of the 
following: ptc score>0, g score>0, acute thrombotic microangiopathy in the absence of any other cause, or 
other features consistent with AMR (endothelial injury, fibrin thrombi, microinfarctions, interstitial 
hemorrhage), or 2) absence of capillary staining of C4d and the presence of ptc>0 and g>0 or ptc>0 or g>0 
and acute thrombotic microangiopathy, in the absence of any other cause of thrombotic microangiopathy.  
 
Patients who developed subclinical AMR were matched in a 1:3 ratio on HLA-compatibility, ABO-
compatibility, donor type (deceased versus live), history of previous transplant, peak panel-reactive 
antibody/calculated panel reactive antibody, age at transplant, and year of transplant to patients who did not 
develop AMR.  
 
Subclinical episodes of AMR were those that did not have evidence of graft dysfunction, manifested as 
oliguria/anuria, an increase in serum creatinine by >20% from baseline, treatment of cell-mediated rejection 
and/or thrombotic microangiopathy within the two prior weeks, new onset proteinuria, the need for post-
transplant splenectomy, or the need for dialysis at the time of the AMR-defining biopsy. 
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The diagnosis of antibody-mediated rejection (AMR) occurring in the first year post-
transplantation was based on the 2013 international Banff Classification Criteria (39) and defined 
as the presence of circulating donor-specific antibody and either: 1) peritubular capillary staining 
of C4d and at least one of the following: ptc score>0, g score>0, acute thrombotic 
microangiopathy in the absence of any other cause, or other features consistent with AMR 
(endothelial injury, fibrin thrombi, microinfarctions, interstitial hemorrhage), or 2) absence of 
capillary staining of C4d and the presence of ptc>0 and g>0 or ptc>0 or g>0 and acute thrombotic 
microangiopathy, in the absence of any other cause of thrombotic microangiopathy.  
 
Clinical episodes of AMR were distinguished from subclinical episodes by the presence of graft 
dysfunction, manifested as oliguria/anuria, an increase in serum creatinine by >20% from 
baseline, treatment of cell-mediated rejection and/or thrombotic microangiopathy within the two 
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Incompatible live donor kidney transplantation is associated with an increased rate of 
antibody-mediated rejection (AMR) and subsequent transplant glomerulopathy.  For 
patients with severe, oliguric AMR, rapid graft loss is inevitable without timely 
intervention.  We reviewed our experience rescuing kidneys with this AMR phenotype by 
using splenectomy alone (n=14), eculizumab alone (n=5), or splenectomy plus 
eculizumab (n=5).  The study population was 267 consecutive patients undergoing 
desensitization for an HLA-incompatible live donor renal transplant.  In the first 3 weeks 
after transplantation (mean=6 days), 24 patients developed sudden onset oliguria and/or 
rapidly rising serum creatinine with marked rebound of donor specific antibody, and a 
biopsy that showed features of severe AMR.  At a median follow up of 533 days, 4 of 14 
splenectomy alone patients experienced graft loss (median=320 days), compared to 4 of 5 
eculizumab alone patients with graft failure (median=95 days).  No patients treated with 
splenectomy plus eculizumab experienced graft loss.  There was more chronic 
glomerulopathy in the splenectomy alone and eculizumab alone groups at 1 year, while 
splenectomy plus eculizumab patients had almost no transplant glomerulopathy.  These 
data suggest that for patients manifesting early severe AMR, splenectomy plus 






Sensitization to HLA is one of the most significant barriers to access to transplantation.  
For approximately 30,000 patients on the kidney transplant waiting list in the USA, 
sensitization will mean prolonged waiting times and a high wait list death rate (15).   Live 
donor kidney transplantation, through the use of various desensitization protocols, has 
given highly sensitized patients the opportunity to experience the benefits of renal 
transplantation. However, patients who are desensitized do experience higher rates of 
antibody-mediated rejection (AMR) and outcomes are not as good as patients who 
receive HLA compatible kidneys (58).  The main challenge facing the field of HLA 
desensitization is the high rate of chronic glomerulopathy (cg) associated with antibody-
mediated injury and the resultant shortened allograft half-life (104, 105). 
 
Early acute AMR, characterized by deposition of C4d in the peritubular capillaries (PTC) 
and peritubular neutrophil margination in the presence of donor specific antibody (DSA) 
occurs in 20-40 percent of patients after desensitization for an HLA-incompatible 
transplant (80, 102, 106).  Early AMR is usually mild and responds to additional 
treatment with plasmapheresis (PP), intravenous immunoglobulin (IVIg), and anti-CD20 
therapy (16, 41).  However, about 5-10% of patients undergoing desensitization will 
experience a very strong DSA rebound and severe oliguric AMR that can be recalcitrant 
to standard therapy, rapidly resulting in cortical necrosis and graft loss [7].   Rescue 
splenectomy has been described as allograft salvage therapy for patients with this 
phenotype (107).  Newly formed plasmablasts migrate to the spleen, and splenectomy can 
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result in a rapid reduction in DSA production.  PP is then able to clear the remaining 
circulating antibody, and most kidneys will recover function.  However, transplant 
glomerulopathy is accelerated in these grafts.     
 
Eculizumab (Soliris, Alexion) is a humanized monoclonal antibody that binds the 
complement protein C5, preventing cleavage into its effector molecules C5a and C5b, the 
latter of which is required for generation of the membrane attack complex  and cell lysis 
(108).  We reasoned that the mechanism of action of this biologic agent might provide 
protection against antibody-mediated injury to the vascular endothelium preventing 
activation of the cascade that leads to irreversible microvascular coagulative necrosis.  
Blocking acute complement-mediated injury might then allow time for the DSA to be 
removed with aggressive PP therapy.  Early AMR after desensitization is thought to be 
due to anamnestic B-cell activation and is complement-dependent in most cases.   
 
We first used eculizumab in 2004 for patients with severe AMR that could not undergo 
splenectomy [8].  The results were mixed, probably because we had not done anything to 
slow the production of antibody from splenic plasmablasts and at high DSA levels, there 
was still injury occurring.  We hypothesized that combining eculizumab with 
splenectomy and PP might allow these kidneys to be rescued and prevent the acute injury 
that results in transplant glomerulopathy.  In this study we compare the outcomes of 24 
patients with the severe oliguric AMR phenotype who were treated with either 
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splenectomy, eculizumab, or splenectomy combined with eculizumab, in addition to PP, 





This is a retrospective analysis of an approved prospective database which undergoes 
annual review by the Johns Hopkins Institutional Review Board.  All patients were 
treated with a standardized treatment protocol.  An Investigational New Drug application 
for off-label compassionate use of eculizumab was initially approved by the Food and 
Drug Administration for the indication of severe AMR in 2004.   
 
Between October 2003 and June 2012, 267 patients underwent live donor kidney 
transplantation at Johns Hopkins and had detectable DSA prior to the initiation of 
desensitization (HLA incompatible).  The study cohort consists of all patients who were 
recipients of HLA- or HLA- plus ABO-incompatible live donor kidney transplants and 
developed severe oliguric AMR within the first month after transplantation.  We define 
this phenotype as consisting of sudden, early renal dysfunction with oliguria (urine output 
falling by > 50% in 24 hours) and/or a 50% rise in serum creatinine, with a concomitant 
increase in DSA and histology consistent with AMR (including features associated with 
severe AMR such as extensive endothelial injury, fibrin thrombi, micro-infarctions, 
interstitial hemorrhage), as well as C4d and margination of neutrophils in the PTC.  All 
patients were treated with PP and low-dose IVIg during their AMR episode.  Additionally, 
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the patients either received splenectomy, eculizumab, or both splenectomy and 
eculizumab.  Splenectomy was performed emergently as soon as the diagnosis of severe 
AMR was confirmed. Clinical and biochemical data abstracted from the database, and 
pathologic data from renal allograft tissue obtained at the time of the AMR-defining 
episode and from protocol biopsies at 6 and 12 months were analyzed.   
 
Eculizumab Administration 
Eculizumab was given intravenously at a dose of 1200 mg on the day the diagnosis of 
AMR was confirmed.  A dose of 900 mg was administered the next day.  After each PP 
treatment for the AMR episode an additional dose of 600 mg of eculizumab was given.  
This dosing was based on the pharmacokinetic and pharmacodynamic studies from the 
index case in 2004 and confirmed in subsequent patients (26, 109).  During PP and up to 
1 month after the initial dose, patients also received a weekly dose of 900 mg. Beginning 
on week 5, doses of 1200 mg were administered every two weeks for patients who 
remained on the drug.  Eculizumab was discontinued when either the DSA dropped 
below a strength that would yield a positive flow cytometric crossmatch (FCXM) 
(roughly 5,000 mean fluorescence intensity [MFI]) or AMR had resolved on biopsy. 
 
Desensitization and immunosuppression 
All patients received PP and DSA monitoring prior to the transplant and post-transplant 
by protocol as previously described (15). Every other day PP treatments were followed 
by the administration of IVIg (intravenous cytomegalovirus immune globulin, 100mg/kg, 
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Cytogam®, CSL Behring).  21 of 24 patients received at least 1 dose of anti-CD20 
antibody (rituximab, 375 mg/m
2
, Rituxan®, Genentech).   
 
Mycophenolate mofetil (2 g/day) and tacrolimus (target serum level 8 to 12 ng/ml) were 
administered beginning with the first pre-transplant PP treatment. Induction 
immunosuppression therapy was achieved with either daclizumab (2mg/kg, Zenapax®, 
Roche) or antithymocyte globulin (1.5 mg/kg daily for 5 days, Thymoglobulin®, 
Genzyme).  Methylprednisolone 500 mg was administered daily for three days beginning 
intraoperatively; corticosteroids were then tapered over five days, and converted to 




Crossmatch tests, including anti-human globulin-enhanced lymphocytotoxicity (AHG-
CDC) with T cells, one wash CDC (1wCDC) with B cells, and flow cytometry with T 
and B cells were performed.  If present, antibodies were characterized in tests of 
multianalyte beads bearing individual class I and/or class II phenotypes (LIFEMATCH-
ID, Gen-Probe, Stamford, CT) and, when needed for confirmation, tests of multianalyte 
beads bearing single antigens (LABscreen Single Antigens, One Lambda, Canoga Park, 
CA). Results were read on a Luminex® fluoroanalyzer with results expressed as mean 
fluorescence intensity. Titers for DSA were based upon IgG antibodies.  
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Reactions with test beads yielding MFI >1000 were considered positive.  Although the 
sensitivity of detection varies for different HLA antibodies, in general, positive flow 
cytometric crossmatch (FCXM) tests correlated with the following MFI values from the 
solid phase immunoassays: >5000 on phenotype panels and >10-15,000 on single antigen 
panels.  Positive complement-dependent cytotoxicity crossmatch (CDC) results were 
associated with >10,000 MFI on phenotype panels.  However, caution must be exercised 
when interpreting these results due to significant variation in the results of solid phase 
assays within and especially between laboratories and nothing replaces actually 
performing the crossmatch. 
 
In most cases, sera were available from the pre-desensitization, post-transplantation nadir, 
and AMR samples, and they were retested since major changes in testing technology and 
methodology occurred over the period of the study.  When donor cells were available 
actual crossmatch testing was performed, otherwise, the results represent virtual 
crossmatches. 
 
Histology and Immunohistochemistry 
C4d staining was performed on frozen tissue by indirect immunofluorescence using anti-
human C4d antibody (Quidel, San Diego, CA) at 1:40 dilution, followed by secondary 
antibody (fluorescin-isothiocyanate-conjugated goat anti-mouse IgG) or on paraffin 
embedded tissue sections using a rabbit polyclonal anti-human antibody at a 1:50 dilution, 
coupled with a biotin free polymer detection system (Lecia).  
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Biopsies were evaluated for cell mediated rejection and AMR based on updated 
Banff ’97 criteria (110, 111). C4d staining was considered positive if present in ≥ 50% of 
the PTC with intensity ≥1+ (C4d2-3).  The Banff histological parameters were used to 
score biopsies for:  tubulo-interstitial scarring as ci (interstitial fibrosis) + ct (tubular 
atrophy); presence of glomerulitis:  g ≥ 1; peritubular capillaritis:  ptc ≥ 1; and chronic 
transplant glomerulopathy: cg ≥ 1.   
 
Renal Function 
Renal function was assessed as the serum creatinine nadir in the month following kidney 
transplantation.  For patients who had functioning grafts at 1 year, the serum creatinine 
on the day of the 1-year allograft biopsy (or closest to that date) was used as the 1-year 
estimation of allograft function.   
 
Statistical Analysis 
Data were analyzed using Stata (Stata Statistical Software: Release 12.  College Station, 
TX: StataCorp LP).  Patient and graft survival were explored using Kaplan-Meier 
analysis and compared between groups using log-rank testing.  Between-group 
comparisons were made using analysis of variance, Fisher's exact test, and Kruskal-







Of 267 HLA-incompatible kidney transplants performed during the study period, we 
identified 24 patients with early severe AMR (9.0%), 14 of whom received splenectomy 
alone as salvage therapy.  Five received eculizumab alone, and another 5 received a 
combination of splenectomy and eculizumab. In addition to HLA-incompatibility, 1 
splenectomy alone patient, 2 eculizumab alone patients, and 1 combination treatment 
patient were also ABO-incompatible with their donor.  In only the combination therapy 
patient could the AMR be attributed to isohemagglutinin rebound rather than DSA.  
 
Table 1 describes the summary patient characteristics according to therapy received.  The 
majority of patients were female (58.3%) and white (91.7%).  Fifteen patients (62.5%) 
had undergone prior transplantation, including 5 who had undergone more than one 
previous transplant.  Median panel reactive antibody (PRA) was 97 (IQR: 85.5-100). The 
patients underwent a median of 3 (IQR 2-4.5) pre-transplant PP sessions and 12.5 (IQR 
9.5-15) post-transplant sessions, including sessions to treat their index AMR episode.  
The median PRA for the splenectomy, eculizumab, and combined therapy groups were 
99.5% (interquartile range [IQR]: 94-100), 97% (IQR: 85-97), and 86% (IQR: 0-94).   
 
Table 2 provides more individualized information about each patient.  Amongst the 
etiologies for end stage renal disease, congenital anomalies of the kidney and urinary 
tract, diabetes mellitus, focal segmental glomerulonephritis, and glomerulonephritis were 
the most common etiologies, occurring in 6, 5, 4, and 4 patients, respectively.   
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The beginning DSA strength for the 3 groups was not the same.  For the splenectomy, 
eculizumab, and combined treatment groups, 64%, 40%, and 0% started desensitization 
therapy with a positive CDC crossmatch, 29%, 60% and 60% had a positive FCXM, and 
7%, 0%, and 40% had DSA below the FCXM threshold but detectable by Luminex 
testing, respectively.  
 
However, Table 2 shows that the change in DSA strength between the groups from the 
post-transplant nadir to the AMR defining episode was not different.  In fact, the patients 
in the combined treatment group increased from -FCXM strength to a + CDC crossmatch 
representing a very large rebound in DSA.  Thus, the better outcomes and lower rates of 
transplant glomerulopathy in this group cannot be explained by a lower pre-
desensitization DSA level.  
 
Post-Transplantation Events 
Patients were diagnosed with AMR at a median of 6 days post-transplant (IQR 5-9) and, 
of those undergoing splenectomy, the operation was performed at a median of 7 days 
post-transplantation (interquartile range 6-9) (Table 1).  The median number of 
eculizumab doses was 12.5 (interquartile range 4-17).  Of the 14 splenectomy alone 
patients, 4 lost their grafts at a median of 320 days post-transplant (IQR: 62-538).  Four 
eculizumab alone patients experienced graft loss at a median of 95 days (IQR: 44.5-138).  
One-year death-censored graft survival was 77.9% in the splenectomy alone group, 
30.0% in the eculizumab alone group, and 100.0% in the combination treatment group 





At the time of AMR diagnosis, the median serum creatinine (mg/dL) was 2.9 (IQR: 2.3-
3.6), 4.6 (IQR: 4.4-5.3), and 2.1 (IQR: 2.0-2.8) for the splenectomy, eculizumab and 
combination treatment groups, respectively (Figure 2).  By 1 year, the median serum 
creatinine was 1.9 (IQR: 1.5-2.2) for the splenectomy group.  The single patient with a 
functioning graft at 1 year in the eculizumab group had a creatinine of 1.8 mg/dL.  The 
median serum creatinine in the combination treatment group at 1 year was 1.6 (IQR: 1.2-
2.1).   
 
Representative profiles from patients in each treatment group 
Figure 3 demonstrates the changes in serum creatinine and urine output over the course of 
AMR treatment as well as a detailed timeline of peri-transplant antibody-lowering 
therapies for a representative patient from each treatment group. Figure 3a depicts a 
patient who had a sudden onset of anuria and a sharp rise in serum creatinine on post-
transplantation day (PTD) #5 preceded 1 day by the appearance of new class I DSA (A2, 
B7) and a rise in class II DSA (DR15/51) to a +FCXM strength.  The diagnosis of AMR 
was confirmed on PTD # 5 on biopsy, and the splenectomy was performed the same day.  
The patient remained anuric for 10 days and was on dialysis before renal function 
recovered with a return of urine output followed by a fall in serum creatinine.  Coincident 
with the return of urine output the class I and II DSA dropped below the threshold for a 
positive Luminex assay.  The patient’s creatinine returned to 1.2 mg/dL but she 
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developed early transplant glomerulopathy and on PTD #340 she lost her graft during an 
episode of ischemic colitis. 
 
Patient 3b received eculizumab in addition to PP/IVIg and anti-CD20.  This was a pre-
emptive transplant and the patient had normal urine output pre-transplantation.  
Beginning on PTD #3 her creatinine began to increase and her class I DSA  (A2, B35, 
B44) rose sharply.  A biopsy on PTD #4 confirmed early AMR.  The creatinine stabilized 
between PTD #4-6 with daily PP but then began to rise rapidly and on PTD #7 
eculizumab was begun.  DSA continued to increase and peaked on PTD #10.  The kidney 
never regained function and ruptured on PTD #23 requiring emergent transplant 
nephrectomy.  The explant showed severe AMR with cortical necrosis and interstitial 
hemorrhage. 
 
Splenectomy and eculizumab were used to treat patient 3c in addition to PP/IVIg and 
anti-CD20.  The patient’s creatinine began to rise on PTD #6.  DSA to A24, DR11, DR52, 
and DP began to acutely rebound on PTD #4 and then fell on PTD #7 after eculizumab 
was started and a splenectomy was performed.  A return of urine output began within 
hours of the splenectomy and at 1 month the serum creatinine was 1.0 mg/dL.  At 1 year 
the patient’s cg score was 0.   
 
Transplant glomerulopathy and surveillance biopsies 
 
As expected, chronic glomerulopathy (cg) was absent at the time of the AMR-defining 
biopsy.  Figure 4 demonstrates rates of graft loss, missing data, and the evolution of 
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transplant glomerulopathy by treatment group over the year following transplantation.  In 
the splenectomy-alone group at 6 months, there were 3 graft losses and 1 patient did not 
have a biopsy.  1/10 (10%) of patients had a cg score of 2 and 1/10 (10%) had a cg score 
of 3.  The remaining 8/10 (80%) had a cg score of 0.  There were 2 immediate graft 
losses in the eculizumab-alone group.  Of the 3 that made it out to 6 months, 1 patient 
(33.3%) had a cg score of 2, 1 had a score of 1 (33.3%), and 1 had a cg score of 0 
(33.3%). In the combination treatment group, there were no graft losses or missing data, 1 
patient had a cg score of 1 (20.0%), and the remaining 4 (80.0%) had a cg score of 0.  
 
At 12 months, in the splenectomy-alone group there were 4 graft losses and 1 missing 
data point.   2/9 patients (22.2%) had a cg score of > 2, 3/9 (33.3%) had a score of 1, and 
4/9 (44.4%) had a score of 0. The remaining eculizumab-alone patient with a functioning 
graft at 1 year had a cg score of 2.  In the combination treatment group, 1 patient (20.0%) 
had a cg score of 1, and the remaining 4/5 (80.0%) had a score of 0.  In summary, in the 
splenectomy-alone group only 29% of the patients had functioning allografts and a 1-year 
biopsy free of transplant glomerulopathy.  In the eculizumab-alone cohort all grafts were 
either lost or had transplant glomerulopathy.  In the combined group 80% of the patients 
had functioning grafts free of transplant glomerulopathy. 
 
Figure 5 demonstrates the pathologic findings on the AMR-defining biopsy and on 
subsequent biopsies at either 6 months or 1 year in a representative patient from each 
treatment group.  The patient in the splenectomy-alone group had severe AMR on her 
index biopsy characterized by diffuse C4d staining with marginating neutrophils and 
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infarcted glomeruli (panels A,B,C).  The 6 month biopsy on this patient showed widening 
of the subendothelial space and cytoplasmic interposition on electron microscopy (D).  
Glomerular double contours are present on the 1 year biopsy (E).   
 
The second panel is from the patient in the eculizumab-alone group.  The AMR-defining 
biopsy shows extensive interstitial hemorrhage (F) minimal glomerular damage (G) and 
C4d positivity (H).  The 1-year biopsy demonstrates widening of the subendothelial space 
and cytoplasmic interposition on electron microscopy (I) and an ischemic glomerulus (J).   
 
Panel 3 is from the representative patient in the combination treatment group.  The first 3 
panels from a biopsy at the time of the AMR diagnosis show PTC margination (K), a 
glomerulus with fibrin deposits and thrombotic microangiopathy (L), and positive C4d 
immunofluorescence staining (M).  A biopsy at 1 year has a relatively normal-appearing 




For patients undergoing desensitization prior to live donor kidney transplantation, graft 
loss within the first month from severe AMR remains one of the most off-putting realities 
facing programs considering taking on patients with heightened immunologic risk from 
HLA sensitization.  Not only are these losses devastating on a human level, but 
regulatory benchmarking that does not account for this increased risk liability raises the 
specter of Centers for Medicare & Medicaid flagging and decertification.  In our 
experience from desensitizing 267 patients with DSA, this AMR phenotype occurs at an 
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alarming rate of 9%.  We have previously shown that daily PP, low dose IVIg, and anti-
CD20 are not effective in rescuing these kidneys, and graft loss is almost universal (107).  
This is likely because the strength of the anamnestic responses that produce this 
phenotype overwhelms the capacity of PP to keep pace with new antibody production, 
and anti-CD20 is not effective against plasmablasts that are responsible for this rapid 
antibody release.  We, and others, reported that immediate splenectomy could rescue 
most kidneys undergoing severe, early oliguric AMR (112).  Plasmablasts traffic from 
regional lymph tissue to the spleen before maturing and taking up residence in the bone 
marrow where they are long-lived and protected in a niche microenvironment.  The 
plasmablasts are vulnerable to debulking by virtue of the enrichment of these cells in the 
spleen at the time of a severe AMR.  Indeed, spleens explanted from these patients are 
packed with donor-specific plasmablasts and plasma cells (113-115). 
 
While splenectomy has been effective at decreasing rates of early graft loss to acceptable 
levels for patients and regulatory organizations, we have observed in this study that 
allografts rescued by splenectomy have a high rate of transplant glomerulopathy within a 
year of the AMR episode and a steady attrition.  Splenectomy appears to produce source 
control of new antibody production but high levels of soluble antibody must still be 
cleared by PP and this takes days to accomplish.  During this time the renal endothelium 
is subjected to unbridled antibody-driven, complement-mediated cytolysis.  Complement 
split products amplify injury through chemotactic signals and recruitment of effector cells.  
The lesions that result in transplant glomerulopathy appear to start during the acute AMR 
episode and in most cases are not due to ongoing antibody injury since PP in this study 
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was continued until DSA was eliminated or reduced below a positive FCXM strength.   A 
mechanistic pathway-driven therapeutic approach, as well as early success in reversing 
AMR in small animal experimental models (116) using complement inhibition prompted 
us to first use eculizumab in a patient experiencing severe AMR in 2004 (26). We were 
also able to work out the pharmacokinetics of using eculizumab concurrently with PP, 
which we think is essential. 
 
In this study, we report the results of three approaches to reversing severe, early AMR 
after desensitization using splenectomy, eculizumab, and a combination of both 
interventions.  In addition to one of these 3 treatment modalities, all patients were treated 
with PP and low dose IVIg and most received anti-CD20.  Splenectomy produced a 
salvage rate of 86% at PTD #60, but by 1 year, only a third of the kidneys were still 
functioning and free from transplant glomerulopathy.  Eculizumab without splenectomy 
was not effective in this small cohort and all 5 patients treated either lost their kidney or 
developed transplant glomerulopathy.  Combining splenectomy and eculizumab produced 
the best results with 100% rescue and graft survival at 1 year.   On 1-year protocol 
biopsies, only 1 patient out of 5 was found to have a cg >0.  Pre-desensitization strength 
differed between the treatment groups with the combination treatment group starting off 
with the lowest level DSA.  However, this did not prevent patients in this group from 
developing severe AMR, and the actual change in antibody strength from the post-
transplant nadir to the AMR episode was as great in the combined group as the other two 
cohorts, suggesting similarly robust anamnestic responses. 
 
 70 
An attractive mechanistic model for explaining the success of the combined intervention 
is that splenectomy removes antibody-producing cells and eculizumab protects the 
endothelium from injury while PP is clearing residual circulating antibody.  In other 
words, the splenectomy increases rescue rates, and the eculizumab prevents transplant 
glomerulopathy.   The protective effect of eculizumab may not be durable and if strong 
DSA is allowed to persist for long periods of time chronic glomerulopathy develops (27).  
For this reason we believe it is important, especially when DSA strength is high as in 
these early AMRs, to deplete the antibody with PP until the FCXM is negative.  
Unfortunately, this will also remove eculizumab, and a dose of 600 mg of this costly drug 
must be given after each plasma exchange.   
 
To date there are only case reports of using eculizumab to reverse AMR in allografts (26, 
117-120).  The Mayo group used eculizumab prophylactically in patients undergoing 
desensitization (27).  They found a significant reduction in AMR, including the 
phenotype described in our study, during the first 3 months after renal transplantation.  
They did not perform post-transplantation PP, and DSA persisted in many of the patients 
in the absence of renal dysfunction and histologic evidence of AMR.  However, some of 
these patients did go on to develop transplant glomerulopathy after the drug was 
withdrawn, and we think this supports our therapeutic design and mechanistic 
explanation for each component in the protocol described here.  Also, since it has not 
been possible to predict which patients will develop early AMR, prophylactic use of 
eculizumab means treating all of the patients who are desensitized, when only 9% of 
them will develop graft-threatening AMR.  It is unclear at this point whether the 
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additional cost of the drug will allow its use in the 91% of patients who will not develop 
severe AMR. 
 
The limitations of this study are due primarily to the nonrandomized methodology and 
the fact that significant changes in technology and best practices occurred over the study 
period.  However, the desensitization protocol remained consistent throughout, and 
changes in DSA testing were mitigated in part by retesting the serum from earlier time 
periods using current techniques. Additionally, the small sample size and the inability 
to adjust for important confounders limits our ability to draw definitive conclusions 




In conclusion, these preliminary data suggest that splenectomy is effective at graft 
salvage, but long-term graft survival is poor due primarily to transplant glomerulopathy.  
Eculizumab alone does not appear to be sufficient to rescue kidneys when very high 
levels of DSA are present, but further work needs to be done to determine its efficacy for 
reversing AMR at lower antibody strengths.   When administered in concert with 
splenectomy, eculizumab may offer the best opportunity for graft salvage and longer-
term graft survival in patients with the most severe, imminently graft-threatening 
presentation of AMR; however, caution must be exercised because of the invasive nature 
of splenectomy and the significant cost of eculizumab. 
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Age at Transplant 
(SD) 
43.7 (14.3) 48.3 (12.4) 27 (4.7) 47.6 (14.6) 0.89 
Female 14 (58.3%) 9 (64.3%) 1 (20.0%) 4 (80.0%) 0.12 
Black Race  2 (8.3%) 1 (7.1%) 0 (0.0%) 1 (20.0%) 0.67 
Median PRA (IQR) 
97 (85.5-
100) 
99.5 (94-100) 97  (85-97) 86 (74-94) 0.17 
History of Prior 
Transplantation 




    0.06 
Luminex+ 3 (12.5%) 1 (7.1%) 0 (0.0%) 2 (40.0%)  
FCXM+ 10 (41.7%) 4 (28.6%) 3 (60.0%) 3 (60.0%)  
CDC+ 11 (45.8%) 9 (64.3%) 2 (40.0%) 0 (0.0%)  
DSA Strength at 
the Time of AMR 
 * †  § 0.53 
Luminex+ 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)  
FCXM+ 6 (30.0%) 4 (36.4%) 2 (40.0%) 0 (0.0%)  
CDC+ 14 (70.0%) 7 (63.6%) 3 (60.0%) 4 (100.0%)  
Induction Agent      
Anti-Thymocyte 
Globulin 
12 (50.0%) 4 (28.6%) 4 (80.0%) 4 (80.0%) 0.02 
Daclizumab 11 (45.8%) 10 (71.4%) 1 (20.0%) 0 (0.0%)  








12.5 (9.5-15) 12 (8-13) 14 (10-15) 21 (15-24) 0.10 
Days Until AMR 
Diagnosis (IQR) 





7 (6-9) 6 (5-8) -- 8 (8-11) 0.08 
SD=standard deviation, PRA=panel reactive antibody, IQR=interquartile range, PP=plasmapheresis; CDC+ 
= complement-dependent cytotoxicity crossmatch positive, FCXM+ = flow cytometric crossmatch positive, 
Luminex+ = negative FCXM but DSA with mean fluorescence intensity > 1,000 on Luminex platform 
* 2 patients did not have a crossmatch available at the time of AMR diagnosis.  
† 1 patient had a negative FCXM, but new anti-B50 antibody. 
§ 1 patient had no detectable donor-specific antibody, but a rebound of anti-A antibody (titer 32). 
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Table 2.  Sensitization, Donor-Specific Antibody Strength, and Treatment of Antibody-






































1 51 F - 95 CDC+ NA NA 2 N -- -- -- 
2 72 F - 62 CDC+ No DSA +FCXM 4 N -- -- -- 
3 46 M Kidney 98 FCXM+ NA NA 7 Y -- -- -- 










4 Y -- -- -- 
5 27 M Kidney 94 CDC+ No DSA +CDC 9 Y -- -- -- 
6 39 F 
Kidney-
pancreas 
100 CDC+ No DSA +CDC 6 Y -- -- -- 







5 Y -- -- -- 
8 61 M - 36 Luminex+ No DSA +FCXM 6 Y -- -- -- 





1 Y -- -- -- 




+CDC 5 Y -- -- -- 
11 47 M Kidney 100 FCXM+ NT +CDC 6 N -- -- -- 
12 64 F Kidney 100 CDC+ No DSA 
+CDC  
(titer 16) 
13 Y -- -- -- 
13 34 F Kidney 86 FCXM+ No DSA +FCXM 5 Y -- -- -- 




+CDC 8 Y -- -- -- 
Eculizumab Alone 







+FCXM 6 Y 3 1 0 
16 32 F - 48 CDC+ +Luminex +FCXM 4 Y 1 2 9 
17 30 M Kidney 85 CDC+ +CDC +CDC 11 Y 2 0 2 
18 20 M 
Kidney x 
2 
99 FCXM+ No DSA 
+CDC  
(titer 8) 
10 Y 0 0 1 
19 28 M Kidney 97 FCXM+ +Luminex +CDC 6 Y 3 3 9 
Splenectomy + Eculizumab 




+CDC 16 Y 2 4 26 
21 52 F Kidney 74 FCXM+ No DSA +CDC 17 Y 1 1 5 




+CDC 6 Y 1 6 16 




+CDC 7 Y 1 6 10 
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9 N 1 3 9 
 
Most patients had multiple DSA, but Luminex MFI listed are for the strongest DSA. 
PRA = panel reactive antibody, AMR = antibody-mediated rejection, CDC+ = complement-dependent 
cytotoxicity crossmatch positive, FCXM+ = flow cytometric crossmatch positive, Luminex+ = negative 
FCXM but DSA with MFI > 1,000 on Luminex platform, MFI=mean fluorescence intensity, NA=not 

















FIGURE 3. Serum creatinine, urine output, antibody levels, and details of peri-transplant 
events in a representative patient from the splenectomy alone group (A), the eculizumab 
alone group (B), and the combination treatment group (C).  
The horizontal axis is relative to day of transplant (day 0), with the first date shown being 
the first day of desensitization therapy. The vertical yellow line represents the day that 
the AMR-defining biopsy was performed. AMR=antibody-mediated rejection, 
PP/IVIg=plasmapheresis and intravenous immunoglobulin, anti-CD20=anti-CD20 
antibody (rituximab). 
 






























Figure 4.  Banff chronic glomerulopathy score at the time of antibody-mediated rejection-
defining biopsy, 6 months, and 12 months post-transplant by treatment received 
  
 
AMR=antibody-mediated rejection; cg=Banff chronic glomerulopathy score 
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Figure 5. Pathologic findings on the antibody-mediated rejection-defining biopsy and 
subsequent biopsies in a patient representative of each treatment group. 
 Splenectomy Alone Group: Antibody-mediated rejection-defining biopsy 
demonstrating (A) peritubular capillaries with marginating neutrophils (arrows; H&E, 
600x), glomerular infarction (B; H&E, 400x), and positive C4d immunofluorescence 
staining (C).  Electron microscopy at 6 months with arrows indicating widening of the 
subendothelial space and cytoplasmic interposition (D).  Biopsy at 1 year demonstrating 
double countors (arrows) of the glomerulus and a cg score of 3 (PAS-MS stain, 600x).  
Eculizumab Alone Group: Antibody-mediated rejection-defining biopsy demonstrating 
interstitial hemorrhage (F; H&E, 400x), minimal glomerular damage (G; H&E, 600x), 
and C4d positivity (H; immunohistochemistry, 400x).  Biopsy at 1 year demonstrating 
widening of the subendothelial space and cytoplasmic interposition (I; arrow; electron 
microscopy) and an ischemic glomerulus with a cg score of 2 (J; PAS-MS, 600x).  
Combination Treatment Group: Antibody-mediated rejection-defining biopsy that 
reveals peritubular capillary margination (K; H&E, 600x), a glomerulus with thrombotic 
microangiopathy (L; H&E, 600x) and positive C4d immunofluorescence staining (M).  
Biopsy at 1 year demonstrating relatively normal glomerulus (N; electron microscopy) 
and a borderline cg score of 0-1 (O; PAS-MS, 600x).  
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CHAPTER 5 - Conclusion 
 
This work has examined several challenges associated with kidney transplantation in 
immunologically high-risk patients. First, the risks of graft loss and mortality for 
incompatible live donor kidney transplant (ILDKT) recipients have never been previously 
quantified precisely or in a multi-center fashion. Compared to compatible recipients, 
patients who were positive Luminex, negative flow crossmatch (PLNF) had a similar risk 
of graft loss; however, positive flow, negative cytotoxic crossmatch (PFNC) patients 
(aHR=1.64, 95% CI: 1.15-2.23, P=0.007) and positive cytotoxic crossmatch (PCC) 
patients (aHR=5.01, 95% CI: 3.71-6.77, P<0.001) had increased graft loss in the first year. 
Interestingly, the risk of graft loss attenuated somewhat for PCC patients after the first 
year, but continued to remain elevated compared to compatible recipients (aHR=1.80; 
95% CI: 1.42-2.29; P<0.001). As with graft loss, PLNF patients had a similar risk of 
death compared to compatible patients; however, PFNC (aHR=2.04;95%CI: 1.28-3.26; 
P=0.003) and PCC transplantation (aHR=4.59; 95%CI:2.98-7.07; P<0.001) were 
associated with increased mortality. PCC recipients saw a similar attenuation in the 
increased risk of death after the first year post-transplant as they did with graft loss 
(aHR=1.51; 95% CI: 1.13-2.03; P<0.001). These findings were then used to quantify the 
risk of flagging by the Centers for Medicare and Medicaid Studies (CMS) for regulatory 
scrutiny. Compared to equal-quality centers performing no ILDKT, centers performing 
5%, 10%, or 20% PFNC had a 1.19, 1.33, and 1.73-fold higher odds of flagging. Centers 




ILDKT patients are at particularly high risk of developing antibody-mediated rejection 
(AMR), and it has been unclear in the literature if AMR differentially affects graft 
survival by transplant phenotype (39). Examining the Johns Hopkins Hospital transplant 
population and using a robust, up-to-date definition of AMR, we formed the largest 
cohort in existence of AMR patients. We demonstrated that the incidence of AMR varies 
dramatically by transplant phenotype. Compatible live donor recipients have an AMR 
incidence of 0.7%, but live donor HLA-incompatible recipients have an incidence of 
45.1%. The risk of graft loss appears to vary by phenotype as well. While live donor 
ABO-incompatible recipients do not appear to have an increased risk of graft loss, live 
donor HLA-incompatible recipients have a 6.29-fold increase in the risk of graft loss 
(95% CI: 3.81-10.39; P<0.001). 
 
Finally, in studying AMR in ILDKT patients, it became clear that there exists a 
particularly severe form of AMR that rapidly leads to graft loss without timely and 
aggressive intervention. In examining the Hopkins experience with early, severe AMR, 
we identified three different approaches to graft salvage, in addition to the standard of 
care of plasmapheresis, intravenous immunoglobulin, and anti-CD20 therapy--
splenectomy, eculizumab, and a combination of both interventions. Splenectomy alone 
produced a reasonable immediate salvage rate of 86% at post-transplant day#60, but by 1 
year, only a third of the kidneys were still functioning and free from transplant 
glomerulopathy.  Eculizumab without splenectomy was not effective in this small cohort, 
and all 5 patients treated either lost their graft or developed transplant glomerulopathy.  
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Combining splenectomy and eculizumab produced the best results with 100% rescue and 
graft survival at 1 year.   On 1-year protocol biopsies, only 1 patient out of 5 was found to 
have transplant glomerulopathy. 
 
These results have spurred a number of new scientific questions, and the development of 
these study cohorts has allowed us to begin to answer some of these questions. For 
example, linking the ILDKT multi-center cohort to Medicare claims data will allow us to 
answer a number of important questions about outcomes of ILDKT patients in terms of 
infectious complications and the development of malignancies. The AMR cohort will 
enable us to quantify the outcomes of patients who develop concurrent AMR and various 
types of T-cell-mediated rejection and explore for differences in graft outcomes between 
patients developing C4d-positive AMR and C4d-negative AMR. Despite the many 
clinical and regulatory challenges that remain in optimizing the care of ILDKT patients, 
ILDKT is an exciting field on the cutting edge of science and clinical care. More 
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• Advanced Trauma Life Support Certification (03/2014) 
• Peer Reviewer, Archives of Surgery (2012-2013) 
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• Cardiovascular and Respiratory Section Editor. In: Meguid RA, Van Arendonk  KJ, 
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 • Spanish (fluent) 
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